Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma
- 1 January 1990
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 26 (11-12), 1152-1156
- https://doi.org/10.1016/0277-5379(90)90275-x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- INDUCTION OF HYPERTHYROIDISM BY INTERFERON-α-2bThe Lancet, 1989
- Fluctuations of Plasma β2-Microglobulin, Soluble Interleukin 2 Receptor and Interferon-Gamma Concentrations after Adoptive Immunotherapy with High-Dose Interleukin 2 and Lymphokine-Activated Killer CellsImmunobiology, 1989
- Induction of circulating tumor necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patientsJournal of Clinical Immunology, 1988
- An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancerEuropean Journal of Cancer and Clinical Oncology, 1988
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsNew England Journal of Medicine, 1988
- Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patientsBlood, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Thyroid Autoimmunity in Patients on Long Term Therapy with Leukocyte-Derived Interferon*Journal of Clinical Endocrinology & Metabolism, 1986
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- Interleukin-2 augments natural killer cell activityNature, 1981